Floatz logo

ELGEMTUMAB

HER2 + Breast Cancer

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

188 Active assets in the HER2 + Breast Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
Jazz Pharmaceuticals
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BB
Epirubicin
Shanghai JMT-Bio Inc.
Phase 3BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB

View all 50 →

Same molecule, other indications

ELGEMTUMAB is also rated in:

Advanced HER2-positive Breast Cancer or Gastric CancerDormant
CC
Indicative ·
47 / 100
View asset →
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →